The present study investigated the role of mineralocorticoid receptors (MR) and glucocorticoid receptors (GR) in the expression of habituation of the hypothalamic-pituitary-adrenal (HPA) axis response to stress. Male rats were restrained for 1 h per day for six consecutive days. On day 6, 1 h prior to restraint stress, both restraint-naive and repeatedly restrained rats were injected s.c. with either vehicle (propylene glycol) or one of three corticosteroid receptor antagonist treatments: selective MR antagonist (RU28318 or spironolactone), selective GR antagonist (RU40555), or both MR and GR antagonists combined (RU28318+RU40555). Blood samples were collected for corticosterone measurement at the beginning of stress, during stress, and 1 h after stress termination. Repeated restraint stress produced signi®cant habituation of corticosterone responses. Acute treatment with the combined MR and GR antagonists prevented the expression of habituation. When tested alone, the MR antagonist also blocked the expression of corticosterone-response habituation, whereas the GR antagonist had no effect. Neither the MR, nor the GR antagonists alone, signi®cantly altered the corticosterone response to restraint in rats exposed to restraint for the ®rst time. The ®nal experiment examined the corticosterone response to a corticotropin releasing hormone (CRH, 3 mg/kg i.p.) challenge. Neither previous exposure to restraint or acute pretreatment with the combined MR and GR antagonists (RU28318+RU40555) altered the corticosterone response to CRH challenge. This result indicates that the expression of habituation and its blockade by corticosteroid receptor antagonists is not a result of altered pituitary-adrenal response to CRH. Overall, this study suggests that MR plays an important role in constraining the HPA axis response to restraint stress in restraint-habituated rats. The dependence of the HPA axis on MR-mediated corticosteroid negative feedback during acute stress may be an important mechanism that helps maximize the expression of stress habituation and thereby minimize exposure of target tissues to corticosteroids in the context of repeated stress.
Repeated exposure to stress often leads to adaptation within stress response systems that is evident by a change in the magnitude of subsequent elicited stress responses. In some cases, repeated stress leads to an enhanced or sensitized stress response and in other cases it leads to a blunted or habituated stress response (1, 2) . Although some of the conditions that lead to stress response sensitization or habituation have been characterized, there is very little understanding of the mechanisms responsible for this adaptation. We have studied a stress habituation paradigm in which rats were repeatedly exposed to restraint stress. Our studies focused on the hypothalamic-pituitary-adrenal (HPA) axis as a stress response system by which to monitor the habituation process (3, 4) . For the studies reported here, we considered the possibility that corticosterone negative feedback plays an important role in the expression of HPA axis response habituation.
Two intracellular corticosteroid receptor types were identi®ed (5±7) which participate in corticosteroid negative feedback (8) . One receptor type, the mineralocorticoid receptor (MR or type I), has a high af®nity for corticosteroids and is believed to be predominantly occupied (greater than 70±90%) by corticosterone even under resting conditions during the circadian trough (7, 9) . The second receptor type, the glucocorticoid receptor (GR or type II), has a lower af®nity for corticosteroids. Only during periods of high circulating corticosteroids, such as during stress or the circadian peak, do GR become substantially occupied (7, 10) .
Functional differences between MR and GR in mediating corticosteroid feedback inhibition have been determined in part by the utilization of selective MR and GR antagonists (11, 12) . In a previous study, we found that acute treatment of rats with the selective MR antagonist, RU28318, produced elevated basal corticosterone levels in the circadian trough, but not during the circadian peak (13) . In addition, the MR antagonist did not alter corticosterone secretion in response to restraint stress administered during either the circadian trough or peak. Weidenfeld and Feldman (12) also observed no effect of RU28318 treatment on acute stress, although Ratka et al. (11) found that RU28318 treatment led to sustained stress levels of corticosterone after exposure to a novel environment. With respect to studies blocking GR, we found that the selective GR antagonist RU40555 (14) had no effect on basal or restraint stress corticosterone levels (13) . Another GR antagonist, RU38486, was found by others to interfere with corticosteroid negative feedback during stress (11, 12) . The discrepancy between the effects of these two GR antagonists may be due to the dose of RU40555 used in our study. Due to limited solubility, RU40555 appears to occupy approximately 50% of GR (13, 14) , whereas the dose of RU38486 used by others may occupy a signi®cantly higher percentage of GR. In the only study to block both MR and GR during stress, we found that combined treatment with RU28318 and RU40555 produced an elevation of basal and stress corticosterone levels (13) . These studies and others support the belief that MR maintains low basal activity of the HPA axis during the circadian trough (8, 15, 16) and that GR, with facilitation by MR, constrains the increased HPA axis activity present during the circadian peak and during acute stress (13, 17, 18) .
Although these studies provide important insights into the role of corticosteroid feedback in the daily operation of the HPA axis, the role of corticosteroid feedback in the habituation of the HPA axis to repeated or chronic stress remains unclear. It has yet to be determined whether habituation of the HPA axis is dependent on corticosterone negative feedback. At a systems level, habituation of the HPA axis response to repeated stress must be a result of at least one of the following changes in the system's response to acute stress: (i) there is a change in the neural input to the axis, such that there is a decreased excitatory input or there is an increased inhibitory input, and/or (ii) there is a change in the response of the axis to neural input, such that there is a decreased response to excitatory input or there is an increased response to inhibitory input. Corticosteroid negative feedback may modulate both the neural input to the HPA axis (indirect negative feedback) and how the axis responds to that neural input (direct negative feedback) (8) . Thus, corticosteroids may be an important contributor to the ability of the HPA axis to express habituation. To test this prospect, we investigated the role of both MR and GR activation in the ability of the HPA axis to express habituation to repeated restraint stress in rats. MR antagonists (RU28318 or spironolactone) and the GR antagonist (RU40555) were administered individually or simultaneously (RU28318+RU40555) to restraint naive or restraint habituated rats. Additionally, we used CRH challenge in combination with corticosteroid receptor antagonists to determine if habituation involves a change in pituitary sensitivity to CRH, or a change in corticosteroid negative feedback sensitivity at the level of the pituitary.
Materials and methods

Subjects
Subjects were young adult, male Sprague-Dawley rats supplied from Harlan Sprague-Dawley (Indianapolis, IN, USA) with weights ranging from 250±350 g. Rats were housed in hanging wire mesh cages (two or three per cage) and were maintained on a 12-h light-dark cycle (lights on at 07.00 h). After arrival at the University of Colorado animal facilities, rats were allowed 2 weeks to acclimate to their home cages. Rat chow and water were provided ad libitum. All treatments and blood samples took place during the ®rst half of the light period. All procedures were approved by the University of Colorado's Animal Care and Use Committee.
Glucocorticoid and mineralocorticoid receptor antagonist treatment
The glucocorticoid receptor antagonist, RU40555, and the mineralocorticoid antagonist, RU28318, were donated by Roussel Uclaf (now Hoescht Marion Roussel; Romainville, France). The mineralocorticoid receptor antagonist, spironolactone, was purchased from Sigma (St Louis, MO, USA). The doses of RU40555 (30 mg/kg) and RU28318 (50 mg/kg) used were based on previous evaluation where functional studies and receptor binding assays demonstrated selective antagonism of the glucocorticoid and mineralocorticoid receptors, respectively (13, 14) . RU28318 was found to occupy almost 100% of available MR. Although the dose of RU40555 used in these studies appears to only occupy approximately 50% of available GR, we have found that this dose completely blocked dexamethasone (50 mg/kg s.c.) suppression of stressinduced corticosterone secretion (14) . Due to poor solubility of RU40555, we were not able to use higher doses of this drug. Both RU40555 and RU28318 were dissolved in propylene glycol and the injections were given s.c. (3 ml/kg). For combined MR and GR antagonist treatment, the drugs were dissolved together into a single antagonist cocktail solution. For vehicle treatment, rats were given an equal volume s.c. injection of propylene glycol. In experiment 5, spironolactone was used as an alternative mineralocorticoid receptor antagonist (19) . The dose used was based on pilot studies examining the effect of a range of spironolactone doses (25±100 mg/kg s.c.) on basal and acute stress-induced corticosterone secretion. The dose of 100 mg/kg was found to signi®cantly increase basal concentrations of corticosterone without affecting corticosterone secretion during restraint stress (data not shown). Spironolactone was also dissolved in propylene glycol and administered s.c.
(1 ml/kg). All antagonist injections were administered 1 h prior to subsequent treatment (restraint or CRH injections).
Restraint stress
Restraint stress consisted of placing rats, for 1 h, in well ventilated adjustable length cylindrical plexiglas tubes (6.3 cm diameter and 15.5t2.5 cm length). Restrained rats were placed on a table top in a room adjacent to the rat's home-cage room. Rats that were given repeated restraint were restrained once a day at the same time each day. Restraint may be considered an example of a psychological or processive stressor in which the triggering of a stress response results from the situation (of being trapped in the tube) rather than a result of direct noxious stimuli (20) .
Experiments 1±5: Effect of corticosteroid receptor antagonists on the expression of habituation.
Experiment 1
The ®rst experiment used a combined within and between subjects design to examine whether acute treatment with the combined MR and GR antagonist cocktail has an effect on the expression of habituation as determined by corticosterone secretion. For the within subjects component of the experiment, all rats (n=12) were restrained daily for 6 consecutive days. On the days 1, 5, and 6 of restraint, blood samples were taken immediately after the onset of restraint (determination of basal corticosterone levels), 30 and 60 min into restraint (determination of stress-induced corticosterone levels), and 1 h after the termination of restraint (assessment of recovery from restraint). For the between subjects component of the experiment, rats were randomly divided into two groups (n=6) that on day 6 of restraint were either pretreated with the combined MR and GR antagonist cocktail or vehicle.
Experiments 2±5
These experiments used a 2r2 (restraint experiencerdrug condition) between groups design (n=8) to examine the effect of acute corticosteroid receptor antagonist treatment or vehicle treatment on the corticosterone response to restraint in rats either experiencing restraint for the ®rst time or rats that had ®ve previous daily exposures to restraint. For the second experiment, blood samples were taken immediately after the onset of restraint, 15, 30 and 60 min into restraint, and 1 h after the termination of restraint. For this experiment, there were unusually high corticosterone levels at the recovery time-point. Due to concerns about the potentially cumulative stress of restraint and frequent serial blood samples, subsequent experiments did not include the 15 min timepoint.
Experiment 6: CRH challenge
This experiment investigated the possibility that (i) habituation of the corticosterone response to stress is due to decreased responsiveness of the pituitary to CRH, and (ii) that blockade of the expression of habituation by corticosteroid receptor antagonists was a result of disinhibition of the pituitary's response to CRH. The effects of combined MR and GR antagonists (RU28318 and RU40555) on the corticosterone response to a challenge dose of CRH or vehicle were examined in control rats or rats that had received restraint stress on the 5 previous days. Thus, on the test day, control rats or previously restrained rats were challenged with vehicle or CRH after pretreatment with vehicle or the combined MR and GR antagonist (2r2r2 design). Rats were not restrained on the test day except momentarily for blood sample. Pretreatment injections of either the combined MR and GR antagonists or vehicle were administered 1 h prior to the CRH/vehicle challenge. An exogenous CRH challenge was administered by i.p. injection of CRH (3.0 mg/kg; human/rat synthetic corticotropin releasing factor from Sigma, St Louis, MO, USA; freshly dissolved in sterile sodium chloride). A CRH challenge dose that produces an intermediate corticosterone response was selected based on a previous study (21) . Blood samples were taken 60 min after the CRH/vehicle challenge.
Blood sampling procedure
All blood samples were obtained from the tail vein while the rat was in a Plexiglas tube. For the ®rst sample of the session, the tip of the tail was clipped with a razor blade. Approximately 100±300 ml of blood was collected into heparinized polypropylene tubes, and resulting plasma was then stored at x20uC. On each blood sample occassion, blood samples were collected from all animals within approximately four minutes after experimenter entry into the animal room.
Corticosterone assay
Plasma corticosterone was measured by radioimmunoassay. Plasma samples (20 ml) were diluted 50 fold in 0.01 M PBS and then heated for 1 h at 70uC to inactivate corticosteroid binding globulin. Samples (100 ml) and standards (25±2000 pg/tube) were incubated overnight with [ 3 H]-corticosterone (20 000 c.p.m.; New England Nuclear, MA, USA) and rabbit antiserum raised against corticosterone-3-oxime BSA (B3±163; Endocrine Sciences, Calabasas Hills, CA, USA). Antibody-bound corticosterone was separated from free corticosterone by mixing with dextran-coated activated charcoal followed by centrifugation. Radioactivity in the resulting supernatant was then measured with a Packard liquid scintillation analyser. Assay sensitivity was 0.5 mg/100 ml. The within-and between-assay coef®cients of variation for both a low level of corticosterone (5 mg/100 ml) and a moderately high level of corticosterone (20 mg/100 ml) are routinely less than 10% in our laboratory.
Statistical analysis
Overall treatment effects were determined in each experiment by the appropriate multiway analysis of variance (ANOVA). In experiment 1, the corticosterone responses measured on day 1 and day 5 were analysed by a 2r4 repeated measure ANOVA (dayrstress-test time-point). Day 6 data was analysed by a 2r4 mixed design ANOVA (drug conditionrstress-test timepoint). Post-hoc comparisons for a given time-point across days used a repeated-measure Student's t-test, whereas post-hoc comparisons between groups for a given time-point on day 6 used a between groups Student's t-test. In experiments 2±5, corticosterone values were analysed with an initial 2r2r4 (or 2r2r5 for experiment 2) mixed-design ANOVA (restraint experiencerdrug conditionrstress-test time-point). In experiment 6, values were analysed with an initial 2r2r2 between groups ANOVA (restraint experiencerantagonist pretreatmentrCRH challenge). In all experiments, there was an overall signi®cant effect of stress on corticosterone concentrations across the stress-test time-points. Post-hoc analysis examined differences between groups at each time-point using Fisher's least signi®cant difference test. Data presented in the tables and ®gures are group meanstSEM.
Results
Experiment 1: Within and between groups comparison of the effect of combined MR and GR antagonists (RU28318+RU40555) on the expression of habituation.
There was a signi®cant habituation of the corticosterone response to restraint stress on day 5 compared to day 1 [F(1,11)=23.1, P=0.001] (Fig. 1 ). Student's dependent t-tests indicated that the 30 min time-point during the stress-test on day 5 was signi®cantly lower than the 30 min time-point on day 1 (P<0.01). The vehicle pretreatment on day 6 may have partially interfered with the expression of habituation since the vehicle-treated rats had a greater corticosterone response during the 30-min time-point on day 6 than they had on day 5 (Student's depentent t-test, P<0.05). MR and GR blockade on day 6 produced a large increase in plasma corticosterone levels at the 30 and 60 min time-points compared to the response on the previous day (Student's dependent t-test, P<0.01). In addition, the corticosterone response on day 6 of drug-treated rats was also signi®cantly greater than their response on day 1 when comparing the 60 min time-points (Student's dependent t-test, P=0.05). Finally, the corticosterone response of the drug treated rats was signi®cantly greater than that of the vehicle treated rats for the 30 and 60 min timepoints (repeated measure) on day 6 [F(1,10)=16.3, P=0.002].
Experiment 2: Between groups comparison of the effect of combined MR and GR antagonists (RU28318+RU40555) on the expression of habituation Although in experiment 1 drug treatment appeared to completely block the expression of habituation, there was not a direct comparison examining the effect that MR and GR blockade has on corticosterone levels in rats exposed to restraint stress for the ®rst time. Thus, the second experiment used a between groups design to examine the effect of MR and GR blockade in rats that were exposed to restraint stress for either the ®rst time or for the sixth time.
Repeated restraint stress produced a signi®cant habituation of the corticosterone response to restraint (Fig. 2) . This was supported statistically by comparing the response of vehicletreated rats exposed to restraint for the ®rst time or the sixth time [F(1,14)=5.7, P=0.032]. Post-hoc analysis indicated that the repeated-restraint/vehicle group had signi®cantly lower corticosterone levels than the single-restraint/vehicle group at the 15 and 60 min time-points (P<0.05, Fisher's least signi®cant difference). Acute treatment of rats with MR and GR antagonists increased basal corticosterone levels and completely blocked the expression of habituation. Thus, repeated-restraint rats that were pretreated with drug had signi®cantly higher corticosterone levels at every time-point than repeated-restraint rats treated with vehicle. Drug treatment also produced a trend for an increase in corticosterone levels of rats exposed to restraint for the ®rst time. In the third experiment, repeated restraint stress also produced a signi®cant habituation of the corticosterone response to restraint [F(1,14)=8.6, P=0.011] (Fig. 3) . Pretreatment with the GR antagonist did not interfere with the expression of habituation, nor did it have an effect on rats that were restrained for the ®rst time. (Fig. 4) . Acute pretreatment of rats with the MR antagonist RU28318 produced a small increase in basal corticosterone levels that did not reach statistical signi®cance [F(1,28)=3.8, P=0 .060]. RU28318 treatment completely blocked the expression of habituation. Thus, repeated-restraint rats that were pretreated with drug had signi®cantly higher corticosterone levels at the 30 and 60 min time-points than repeated-restraint rats treated with vehicle (P<0.05, Fisher's least signi®cant difference). Drug treatment also produced a trend for an increase in corticosterone levels of rats exposed to restraint for the ®rst time. Corticosterone response to six daily restraint stress sessions with combined mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) antagonist treatment before the sixth session. Rats were restrained for 1 h on six consecutive days. On day 6, rats were injected s.c. with a combined MR and GR antagonist (50 mg/kg RU28318+30 mg/kg RU40555) or vehicle (3 ml/kg propylene glycol) 1 h prior to restraint stress. Blood samples were taken before (0 min), during (30 and 60 min) and 1 h after (120 min) restraint on days 1, 5 and 6; *P<0.05, vs vehicle group at same time-point on same day, Student's t-test. The left panel shows the corticosterone response of all rats on day 1 and day 5 (n=12). The right panel shows the corticosterone response of rats on day 6 after vehicle or drug pretreatment (n=6).
Experiment 5: Between groups comparison of the effect of a different mineralocorticoid receptor antagonist (spironolactone) on the expression of habituation
The ®fth experiment was conducted to see if acute treatment with a different MR antagonist (spironolactone) would also be suf®cient to block the expression of corticosterone habituation. The pattern of results for corticosterone levels in this experiment was similar to that in experiment 4; however, the magnitude of the corticosterone response habituation was less pronounced and did not reach statistical signi®cance [F(1,14)=3.4, P=0.085] (Fig. 5) . There was an overall effect for spironolactone to increase corticosterone levels [F(1,28)=6.7, P=0.015]. Spironolactone produced a small, but signi®cant increase in basal corticosterone levels (0 time-point, P<0.05, Fisher's least signi®cant difference). At the other time-points spironolactone produced a larger increase in corticosterone levels, but these effects did not reach statistical signi®cance (P-values ranging from 0.07±0.10). Importantly, consistent with experiment 4, there was no trend for an expression of habituation in rats that were acutely treated with the MR antagonist spironolactone. (Fig. 6) . However, there was no signi®cant difference in the corticosterone response to CRH in control vs repeatedrestraint rats. There was a small, but overall signi®cant increase in corticosterone levels of all groups pretreated with the MR and GR combined antagonists [F(1,40)=6.53, P=0.015]. However, post-hoc tests revealed no signi®cant differences between any antagonist vs vehicle comparison for the same previous restraint experience and vehicle/CRH treatment.
Discussion
HPA axis habituation
These studies demonstrated a robust habituation of the corticosterone response to repeated restraint stress that was evident by the ®fth daily restraint stress session. Habituation of the corticosterone response to restraint has been found in many (22±25), but not all studies (26, 27) . The decreased corticosterone response to repeated restraint probably re¯ects a habituated response throughout the entire HPA axis. Another study has found habituation of ACTH responses to repeated restraint stress (corticosterone was not measured) (28) . Habituation of the HPA axis response must be a result of either altered neural input to the axis, or an altered response of the axis to neural input. In this study, there was no difference in the corticosterone response to a CRH challenge between restraint-naive or restraint-habituated rats. Thus, habituation of the corticosterone response to restraint appears to be the result of changes at the level of the paraventricular nucleus of the hypothalamus or elsewhere in the brain, and expression of this habituation appears to depend on corticosteroid negative feedback.
Restraint
Dependence of habituation expression on glucocorticoid negative feedback
We have found in a previous study that the HPA axis response of a rat encountering restraint for the ®rst time is constrained by corticosteroid negative feedback (13) . In that study, acute treatment with the combined MR and GR antagonists produced an elevated plasma corticosterone and ACTH response during 1 h of restraint. In the present study, we examined the possibility that there is a similar dependence of a habituated HPA axis response on corticosteroid negative feedback. In experiment 1, we found that the combined MR and GR antagonist treatment on day 6 prevented the expression of habituation which was evident in the absence of drug treatment on day 5. Interestingly, the corticosterone response of those drug treated rats on day 6 was even greater than it was on day 1. Experiment 1 did not include a direct comparison of the effect that the combined MR and GR antagonists have on the corticosterone response in rats encountering restraint for the ®rst time. If the HPA axis response normally re¯ects the net in¯uence of stimulatory drive and glucocorticoid negative feedback, then removal of glucocorticoid negative feedback by pretreatment with MR and GR antagonists results in unopposed stimulatory drive. One possibility, as discussed above, is that habituation involves a decreased stimulatory input to the HPA axis. If so, blocking negative feedback should not prevent the expression of habituation. Contrary to this prediction, we found in experiment 2 that the corticosterone response to restraint was the same in restraint-naive or restrainthabituated rats pretreated with the combined MR and GR antagonists.
The similar HPA axis response to restraint of naive and habituated rats when pretreated with corticosteroid receptor antagonists does not appear to be the result of a ceiling effect of maximal HPA axis disinhibition. The maximum corticosterone concentrations in experiment 2±5, although variable, are all substantially less than the maximal values (approximately 60 mg/100 ml corticosterone) that we see in this strain of rats (our unpublished observations). Thus, based on the magnitude of drug-induced habituation reversal observed in the present study, it would appear that the expression of habituation is completely dependent on corticosteroid negative feedback. On the other hand, there is some reason to believe from other published studies that a decreased stimulatory input to the HPA axis is a component of stress habituation. Several studies report a habituation of c-fos gene expression with repeated restraint in the paraventricular nucleus of the hypothalamus, as well as in other stressresponsive brain regions (24, 29, 30) . In addition, habituation of c-fos gene induction has been observed in adrenalectomized rats (24) . This would indicate that habituation of the HPA axis response is a result of decreased stimulatory activity throughout stress-responsive brain regions. Further studies will be necessary to resolve this apparent paradox.
Blockade of MR but not GR is suf®cient to prevent expression of habituation
In a previous study, we found that pretreatment of restraint naive rats with either the MR or GR antagonist alone was not able to signi®cantly disinhibit the corticosterone response to restraint (13) . We concluded from our previous study that suppression of the HPA axis during acute stress is dependent on GR mediated corticosterone negative feedback, but that this feedback is facilitated by corticosterone actions at MR. In the present study, we reexamined the effect of administering the MR or GR antagonists alone on the corticosterone response to restraint of rats habituated to restraint stress. Surprisingly, we found that treatment with the MR antagonist alone was suf®cient to block the expression of habituation. Prevailing models of glucocorticoid regulation of HPA axis activity assign to MR predominantly a role for tonic regulation of basal HPA axis activity (8, 15) . However, several recent studies provide evidence for MR involvement in regulating stress responses (11, 13, 31) . The general argument for a lack of MR involvement in regulating phasic HPA axis activity during stress responses stems from the notion that the majority of MR are occupied at all times because of their high af®nity for corticosterone (7) . Our results raise the interesting prospect that the MR antagonist treatment is able to disinhibit the HPA axis during acute stress by blocking a small stress-induced increase in MR occupancy. Alternativly, HPA axis disinhibition may be a result of the substantial reduction in total MR occupancy that occurs after drug injection and before the onset of stress. Reconsideration of basal MR occupancy rates or the primary tonic as opposed to phasic nature of MR mediated corticosterone regulation of HPA axis activity may be warranted.
Site of action for MR-dependent regulation of the expression of habituation
There is very little evidence for MR expression within the paraventricular nucleus as determined by MR mRNA levels or protein-immunoreactivty (32±34). Thus, corticosterone regulation of the expression of habituation via MR is most likely to be a result of corticosterone actions outside of the paraventricular nucleus. There is some expression of MR within the pituitary (10). However, under normal conditions, other studies suggest that there may be very little corticosterone negative feedback at the pituitary due to the strong buffering capacity of high local concentrations of corticosteroid binding globulin (18) . This conclusion is consistent with our CRH challenge studies that found no difference in the corticosterone response to CRH in restraint-naive or restraint-habituated rats pretreated with the combined MR and GR antagonist compared to vehicle pretreatment. It should be noted, however, that several studies have found an increase in stress-induced vasopressin expression in parvocellular paraventricular nucleus neurones after repeated restraint stress (23, 35) . It is possible that acute corticosteroid receptor antagonist treatment blocks a selective inhibitory effect of corticosterone on corticotrope sensitivity to vasopressin. Nevertheless, it is more likely that MR located in the brain are responsible for the blockade of the expression of habituation after treatment with MR antagonists. Possible candidate brain regions for an MR-dependent inhibition of the HPA axis are the hippocampus, septum and frontal cortex (20) . A recent study found that microinjection of the MR
Control
Previously restrained Plasma corticosterone (µg/100 ml) antagonist RU28318 into the hippocampus of rats increased circadian peak basal corticosterone concentrations (36) .
Treatments
Habituation and a shift in the dependence of the HPA axis on MR mediated corticosteroid negative feedback
One possible explanation for a greater effectiveness of MR antagonist treatment in restraint-habituated rats than in restraint-naive rats is that there is less occupancy of GR during restraint in habituated rats. In restraint-naive rats, the large corticosterone response to the ®rst experience of restraint stress may produce suf®cient GR occupancy to compensate for the MR blockade. Thus, MR-dependent corticosterone negative feedback may only help to constrain HPA axis responses when the overall magnitude of the response is relatively small. On the other hand, our results may re¯ect a more generalized increased sensitivity of the HPA axis to MR mediated corticosterone negative feedback that is produced by repeated restraint. Reul and colleagues recently found that one session of acute stress (swim stress) produced a signi®cant increase in hippocampal MR 24 h later, and that this increase in MR was correlated with a greater effect of RU28318 treatment on basal corticosterone levels (37) . An experiment by van den Berg et al. (38) also suggests a shift in MR dependency in repeatedly restrained rats. In that study, brief restraint produced an increase in arterial pressure that was unaffected by pretreatment with RU28318. However, MR antagonist pretreatment suppressed this pressor response after the rats had been exposed for 2 weeks to the daily condition of restraint stress and hyperthermia. An increased dependency of the HPA axis on MR-mediated corticosteroid negative feedback during habituation may play a protective role during repeated stress by minimizing the extent to which the brain is exposed to potentially deleterious effects of excess corticosteroids (39, 40) .
